7Baggers

Genenta Science
(NASDAQ:GNTA) 

GNTA stock logo

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of gliobl...

Founded: 2014
IPO Price: $11.5 (Dec 15, 2021)
Sector: Healthcare
Industry: Biotechnology
Healthcare
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
  • Clinical-Stage Cell & Gene Therapy Company Focused on Cancer Immunotherapy: Genenta Science is developing immunotherapy approaches that leverage genetically modified cells to stimulate anti-tumor immune responses, with programs aimed at solid tumors.
  • Lead Asset Built Around Gene-Modified Hematopoietic Stem/Progenitor Cells: The company’s core platform centers on engineering patient-derived stem/progenitor cells to deliver immunomodulatory signals within the tumor microenvironment, seeking durable immune activation.
  • Value Tied to Clinical Readouts, Safety Profile, and Durability of Response: Near- and mid-term investor focus typically centers on trial milestones, response rates, durability, and adverse-event profile, as these will shape regulatory path and commercial viability.
  • Manufacturing and Scalability Are Key Execution Risks: As a personalized, cell-based modality, Genenta’s progress depends on reliable manufacturing, quality control, and cost/scalability improvements to support broader trials and eventual commercialization.
  • Funding Runway and Partnership Optionality Remain Important Watch Items: Like many clinical-stage biotechs, ongoing operations depend on cash runway management and access to capital; strategic partnerships could provide non-dilutive funding and validation.
Bull Thesis:
  • Differentiated Gene Therapy Platform with Novel MoA: Genenta's Temferon utilizes autologous hematopoietic stem/progenitor cells (HSPCs) to deliver interferon-alpha directly to the tumor microenvironment. This unique mechanism of action aims to overcome limitations of systemic IFN-alpha delivery, potentially leading to improved efficacy and reduced systemic toxicity, offering a significant competitive advantage.
  • Encouraging Early Clinical Data in Difficult-to-Treat Cancers: Initial Phase 1/2 clinical trials for Temferon, particularly in glioblastoma (GBM) – a highly aggressive and difficult-to-treat cancer – have demonstrated a favorable safety profile and promising signs of preliminary efficacy, including extended survival in some patients, which is a significant achievement in this indication.
  • Broad Platform Applicability and Pipeline Expansion Potential: If validated in glioblastoma, the underlying technology of Temferon has the potential for broad applicability across a wide array of other solid tumors. This offers significant opportunities for pipeline expansion into various oncology indications with high unmet medical needs, leveraging a single core platform.
  • Robust Intellectual Property and Strong Scientific Foundation: Genenta's technology is built upon a strong scientific foundation originating from leading research institutions like San Raffaele Hospital. This suggests robust intellectual property protection and a deep understanding of the underlying biological mechanisms, providing a solid base for future development and commercialization.
Bear Thesis:
  • High-Risk, Early-Stage Clinical Development: Genenta Science is a pre-revenue, clinical-stage biotechnology company, meaning its success is entirely dependent on the outcome of ongoing and future clinical trials. Gene therapy development is inherently high-risk, with a significant probability of failure at any stage, from efficacy to safety or manufacturing.
  • Substantial Cash Burn and Future Dilution Risk: Developing complex gene therapies like Temferon requires significant capital investment. Genenta is currently burning substantial cash and, as a pre-revenue company, will likely need to raise additional funds in the future, which could lead to further dilution for existing shareholders.
  • Intense Competition in Oncology and Gene Therapy: The oncology and gene therapy landscapes are highly competitive, with numerous established pharmaceutical companies and emerging biotechs developing novel treatments. Temferon will face significant competition from other gene therapies, immunotherapies, and standard-of-care treatments, potentially limiting market penetration.
  • Manufacturing and Scalability Challenges: Gene therapy manufacturing, especially involving autologous cell therapies, is notoriously complex, expensive, and difficult to scale. Genenta may face significant hurdles in establishing robust, cost-effective, and scalable manufacturing processes for Temferon to meet potential future commercial demand.
  • Limited Clinical Data from Small Patient Cohorts: While early clinical data for Temferon is promising, it is derived from relatively small patient cohorts in Phase 1/2 trials. The results from larger, later-stage clinical trials are crucial for confirming efficacy and safety, and these trials often present different outcomes than initial studies, introducing uncertainty.
Main Competitors:
  • Amgen ($AMGN) (Talimogene laherparepvec (T-VEC, Imlygic)), Amgen has the only FDA-approved oncolytic virus therapy (T-VEC) for melanoma, setting a precedent and directly competing for market share and clinical development strategies in the oncolytic virus space. They also have a vast oncology pipeline.
  • Replimune Group Inc. ($REPL) (RP1, RP2, RP3 (oncolytic immunotherapies)), Replimune is a clinical-stage biotechnology company solely focused on developing a pipeline of oncolytic immunotherapies, directly competing with Genenta Science in the development of next-generation oncolytic viruses for various cancers.
  • Transgene SA ($TNG (Euronext Paris)) (TG6002, BT-001 (oncolytic viruses)), Transgene is a French clinical-stage biotechnology company specializing in oncolytic viruses and therapeutic vaccines for cancer, competing with Genenta Science in developing innovative viral immunotherapies, particularly in the European market.
  • PsiOxus Therapeutics (Enadenotucirev (EnAd)), PsiOxus is a private UK-based clinical-stage company developing a proprietary oncolytic adenovirus platform (EnAd) for various solid tumors, directly competing with Genenta Science's oncolytic virus approach for cancer treatment.
Moat:
The oncolytic virus market is a highly competitive and rapidly evolving segment within oncology and gene therapy. Genenta Science competes with both established pharmaceutical companies like Amgen, which has an FDA-approved oncolytic virus, and numerous clinical-stage biotechs such as Replimune and Transgene, all vying to develop next-generation viral immunotherapies. Genenta's potential moat lies in its proprietary VGNAAT platform, utilizing a modified Vaccinia virus, which may offer unique advantages in terms of tumor tropism, immune activation, and safety profile compared to other viral platforms (e.g., HSV, adenovirus). The company's specific focus on challenging indications like glioblastoma multiforme with its lead candidate, Temferon, also positions it in a high-unmet-need area. Competition is fierce for clinical trial success, regulatory approval, and ultimately, market adoption, with differentiation often coming from demonstrated efficacy, safety, and synergistic potential in combination therapies.
Income Statements:
Quarterly
Annual
    Unit: USD 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD